“…These findings stimulated the development of a group of glucocorticoid analogs, the 21‐aminosteroids (lazaroids), that specifically inhibit lipid peroxidation without glucocorticoid or mineralocorticoid activity, thereby avoiding the complications of GC therapy (42, 59). One representative of this class of drugs, tirilazad, has been shown to be neuroprotective (60) and to inhibit ultraviolet A–induced lipid peroxidation in human dermal fibroblasts (61). This drug is generally well tolerated; adverse reactions (such as local discomfort at the site of infusion and physical signs of local venous irritation), although commonly observed, are usually mild and transient.…”